Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes

Experimental Cell Research

Volumn 315, Issue 7, 2009, Pages 1302-1312

  Pentassuglia, Laura ^a   Graf, Michael ^a   Lane, Heidi ^b   Kuramochi, Yukio ^e   Cote, Gregory ^d   Timolati, Francesco ^a   Sawyer, Douglas B ^c   Zuppinger, Christian ^a   Suter, Thomas M ^a  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^e NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Cardiomyocytes; EGFR; ErbB2; Neuregulin; Tyrosine kinase inhibitor

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CGP 059326; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL DAMAGE; CELL DEATH; CELL FUNCTION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; EXCITATION CONTRACTION COUPLING; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE; HEART VENTRICLE WALL; IN VITRO STUDY; INHIBITION KINETICS; MALE; NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR BLOCKING;

RATTUS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CALCIUM; CELL DEATH; CELLS, CULTURED; DOXORUBICIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GATA4 TRANSCRIPTION FACTOR; MALE; MICE; MITOCHONDRIA; MUSCLE PROTEINS; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; MYOFIBRILS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 63049089461     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2009.02.001     Document Type: Article

References (36)

1. Lee K.F., Simon H., Chen H., Bates B., Hung M.C., and Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378 (1995) 394-398
2. Crone S.A., Zhao Y.Y., Fan L., Gu Y., Minamisawa S., Liu Y., Peterson K.L., Chen J., Kahn R., Condorelli G., Ross Jr. J., Chien K.R., and Lee K.F. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8 (2002) 459-465
3. Ozcelik C., Erdmann B., Pilz B., Wettschureck N., Britsch S., Hubner N., Chien K.R., Birchmeier C., and Garratt A.N. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 8880-8885
4. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., and Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344 (2001) 783-792
5. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., Cameron D., Dowsett M., Barrios C.H., Steger G., Huang C.S., Andersson M., Inbar M., Lichinitser M., Lang I., Nitz U., Iwata H., Thomssen C., Lohrisch C., Suter T.M., Ruschoff J., Suto T., Greatorex V., Ward C., Straehle C., McFadden E., Dolci M.S., and Gelber R.D. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353 (2005) 1659-1672
6. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer Jr. C.E., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., Swain S.M., Pisansky T.M., Fehrenbacher L., Kutteh L.A., Vogel V.G., Visscher D.W., Yothers G., Jenkins R.B., Brown A.M., Dakhil S.R., Mamounas E.P., Lingle W.L., Klein P.M., Ingle J.N., and Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353 (2005) 1673-1684
7. Pentassuglia L., Timolati F., Seifriz F., Abudukadier K., Suter T.M., and Zuppinger C. Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes. Exp. Cell Res. 313 (2007) 1588-1601
8. Kondo R.P., Apstein C.S., Eberli F.R., Tillotson D.L., and Suter T.M. Increased calcium loading and inotropy without greater cell death in hypoxic rat cardiomyocytes. Am. J. Physiol. 275 (1998) H2272-2282
9. Eppenberger H.M., and Zuppinger C. In vitro reestablishment of cell-cell contacts in adult rat cardiomyocytes. Functional role of transmembrane components in the formation of new intercalated disk-like cell contacts. FASEB J. 13 (1999) S84-S89
10. Sawyer D.B., Zuppinger C., Miller T.A., Eppenberger H.M., and Suter T.M. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105 (2002) 1551-1554
11. Zhao Y.Y., Sawyer D.R., Baliga R.R., Opel D.J., Han X., Marchionni M.A., and Kelly R.A. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J. Biol. Chem. 273 (1998) 10261-10269
12. Traxler P., Bold G., Buchdunger E., Caravatti G., Furet P., Manley P., O'Reilly T., Wood J., and Zimmermann J. Tyrosine kinase inhibitors: from rational design to clinical trials. Med. Res. Rev. 21 (2001) 499-512
13. Hoekstra R., Dumez H., Eskens F.A., van der Gaast A., Planting A.S., de Heus G., Sizer K.C., Ravera C., Vaidyanathan S., Bucana C., Fidler I.J., van Oosterom A.T., and Verweij J. Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin. Cancer Res. 11 (2005) 6908-6915
14. Bruns C.J., Solorzano C.C., Harbison M.T., Ozawa S., Tsan R., Fan D., Abbruzzese J., Traxler P., Buchdunger E., Radinsky R., and Fidler I.J. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 60 (2000) 2926-2935
15. Grazette L.P., Boecker W., Matsui T., Semigran M., Force T.L., Hajjar R.J., and Rosenzweig A. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J. Am. Coll. Cardiol. 44 (2004) 2231-2238
16. Baliga R.R., Pimental D.R., Zhao Y.Y., Simmons W.W., Marchionni M.A., Sawyer D.B., and Kelly R.A. NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70(S6K), and MEK-MAPK-RSK. Am. J. Physiol. 277 (1999) H2026-2037
17. Oka T., Maillet M., Watt A.J., Schwartz R.J., Aronow B.J., Duncan S.A., and Molkentin J.D. Cardiac-specific deletion of Gata4 reveals its requirement for hypertrophy, compensation, and myocyte viability. Circ. Res. 98 (2006) 837-845
18. Wang Y.X., and Korth M. Effects of doxorubicin on excitation-contraction coupling in guinea pig ventricular myocardium. Circ. Res. 76 (1995) 645-653
19. Gassmann M., Casagranda F., Orioli D., Simon H., Lai C., Klein R., and Lemke G. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378 (1995) 390-394
20. Miettinen P.J., Berger J.E., Meneses J., Phung Y., Pedersen R.A., Werb Z., and Derynck R. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376 (1995) 337-341
21. Sibilia M., and Wagner E.F. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 269 (1995) 234-238
22. Chen B., Bronson R.T., Klaman L.D., Hampton T.G., Wang J.F., Green P.J., Magnuson T., Douglas P.S., Morgan J.P., and Neel B.G. Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. Nat. Genet. 24 (2000) 296-299
23. Sibilia M., Wagner B., Hoebertz A., Elliott C., Marino S., Jochum W., and Wagner E.F. Mice humanised for the EGF receptor display hypomorphic phenotypes in skin, bone and heart. Development 130 (2003) 4515-4525
24. Crone S.A., Zhao Y.Y., Fan L., Gu Y., Minamisawa S., Liu Y., Peterson K.L., Chen J., Kahn R., Condorelli G., Ross Jr. J., Chien K.R., and Lee K.F. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8 (2002) 459-465
25. Garcia-Rivello H., Taranda J., Said M., Cabeza-Meckert P., Vila-Petroff M., Scaglione J., Ghio S., Chen J., Lai C., Laguens R.P., Lloyd K.C., and Hertig C.M. Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle. Am. J. Physiol. Heart. Circ. Physiol. 289 (2005) H1153-1160
26. Perik P.J., de Vries E.G., Gietema J.A., van der Graaf W.T., Smilde T.D., Sleijfer D.T., and van Veldhuisen D.J. Serum HER2 levels are increased in patients with chronic heart failure. Eur. J. Heart Fail. 9 (2007) 173-177
27. Billingham M.E., Mason J.W., Bristow M.R., and Daniels J.R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat. Rep. 62 (1978) 865-872
28. Shan K., Lincoff A.M., and Young J.B. Anthracycline-induced cardiotoxicity. Ann. Intern. Med. 125 (1996) 47-58
29. Kuramochi Y., Guo X., and Sawyer D.B. Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J. Mol. Cell. Cardiol. 41 (2006) 228-235
30. L. Pentassuglia, D.B. Sawyer, The role of Neuregulin-1beta/ErbB signaling in the heart, Exp. Cell Res. 315 (2009) 627-637.
31. Fukazawa R., Miller T.A., Kuramochi Y., Frantz S., Kim Y.D., Marchionni M.A., Kelly R.A., and Sawyer D.B. Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J. Mol. Cell. Cardiol. 35 (2003) 1473-1479
32. Ewer M.S., Vooletich M.T., Durand J.B., Woods M.L., Davis J.R., Valero V., and Lenihan D.J. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J. Clin. Oncol. 23 (2005) 7820-7826
33. Xin M., Davis C.A., Molkentin J.D., Lien C.L., Duncan S.A., Richardson J.A., and Olson E.N. A threshold of GATA4 and GATA6 expression is required for cardiovascular development. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 11189-11194
34. Fujio Y., Nguyen T., Wencker D., Kitsis R.N., and Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 101 (2000) 660-667
35. Peng X., Guo X., Borkan S.C., Bharti A., Kuramochi Y., Calderwood S., and Sawyer D.B. Heat shock protein 90 stabilization of ErbB2 expression is disrupted by ATP depletion in myocytes. J. Biol. Chem. 280 (2005) 13148-13152
36. Rohrbach S., Niemann B., Silber R.E., and Holtz J. Neuregulin receptors erbB2 and erbB4 in failing human myocardium Depressed expression and attenuated activation. Basic Res. Cardiol. 100 (2005) 240-249